Recombinant Human IL13 Protein (HC0116IL)

Cat.No.

HC0116IL

Synonyms

IL13; interleukin 13; interleukin-13; ALRH; BHR1; IL 13; IL-13;

Species

Human

Accession

IL13

Source

CHO

Predicted N Terminal

Gly 21

Form

Lyophilized from sterile PBS, pH 7.4, 5 % trehalose and 5 % mannitol.

Bio-activity

Measured in a cell proliferation assay using TF1 human erythroleukemic cells (Kitamura, T. et al. 1989, J. Cell Physiol. 140:323.). The ED50 for this effect is typically 0.5-3 ng/mL.

Molecular Mass

Recombinant Human IL13 consists of 112 amino acids and migRates as an approximately 12.5 kDa band in SDS-PAGE under reducing conditions as predicted.

Endotoxin

< 1.0 EU per 1 microgram of protein (determined by LAL method).

Purity

> 92 % by SDS-PAGE.

Background

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.
Isoform 2 may act as an antagonist of EGF action.